Central Alerting System
View Alert

Originator: CMO Messaging

From: CMO Messaging

Issue date: Originally issued on 30-May-2022 14:43:55. This version was issued on 30-May-2022 14:43:55

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive

Action category: Action

Title: Antivirals or Neutralising Monoclonal Antibodies in the Treatment of Hospital-Onset COVID-19

Broadcast content:
The published policy has been updated, effective from 13 June 2022, to link to the published report of the Independent Advisory Group commissioned by the Department of Health and Social Care (DHSC) to advise on the groups of patients likely to be at highest risk of deterioration, hospitalisation or death from a COVID infection.  The report confirms the groups of ‘highest’ risk patients who are potentially eligible for COVID treatments under this policy.  Clinicians are asked to note that figure 1 of the report refers to adults (aged 18 years and over) and figure 2 refers to children (aged 12-17 years).

There are no other material changes to the policy.

Additional information: This alert does not need to be cascaded to Primary Care.

Alert reference: CEM/CMO/2022/009


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency